No Data
No Data
Theriva Biologics Says IDMC Considers VCN-01 to Be Well Tolerated
Theriva Biologics Announces Positive Outcomes From the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination With Chemotherapy for Metastatic Pancreatic Ductal...
Theriva Biologics to Present at the 2025 NeauxCancer Conference
Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $6
Analysts Offer Insights on Healthcare Companies: Myomo (MYO) and Theriva Biologics (TOVX)
Theriva Biologics | 10-K: FY2024 Annual Report